About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT05788432

Sequent Extended Study

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulat...

Lead sponsor: Fundación EPIC•26 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

ORIOL RODRIGUEZ LEOR, MD, PhD

CONTACT

0034934651200 oriolrodriguez@gmail.com

FUNDACION EPIC

CONTACT

0034987876135 iepic@fundacionepic.org

Sponsors

Lead Sponsor

Fundación EPIC

The objective of this multicenter, prospective, non-randomized, postmarket clinical follow-up(PMCF) study is to confirm and support the clinical safety and performance of the Sequent Please Neo in a NON-SELECTED, Real Word population under daily clinical practice when used as intended by the manufacturer to meet EU Medical Device Regulation requirements for post-market clinical follow-up.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.
•Informed Consent Signed.

Exclusion Criteria

•Patient life expectancy less than 12 months.
•Contraindication for antiplatelet therapy.

Related studies

Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

NCT07329699 · Coronary Artery Disease, Chronic Coronary Syndrome, and more

Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study

NCT05365282 · Ischemic Heart Disease, Nerve Injury, and more

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

NCT06863155 · Coronary Artery Disease, Ischemic Heart Disease

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT06779630 · Coronary Artery Disease

TIMELY-PrädiktoR Prospective Study

NCT05461729 · Coronary Artery Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 3, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment2,028

Start dateMar 2023

Last updatedFeb 3, 2026

Condition

Coronary Artery Disease Ischemic Heart Disease

Locations shown

Hospital Universitario de Araba

Alava

Hospital General Universitario de Alicante Dr.Balmis

Alicante

Hospital Universitario de Badajoz

Badajoz

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions